Mr. Louis Laflamme reports

OPSENS' SHAREHOLDERS APPROVE ARRANGEMENT WITH HAEMONETICS

Opsens Inc. shareholders have approved the previously announced acquisition by Haemonetics Corp. of all of the issued and outstanding common shares in the capital of Opsens for $2.90 in cash per share, pursuant to a statutory plan of arrangement under the Business Corporations Act (Quebec).

At the special meeting of shareholders held earlier today, the arrangement was approved by approximately 97.96 per cent of the votes cast by shareholders present virtually or represented by proxy at the meeting. The report of voting results is available under the corporation's profile on SEDAR+.

Subject to receiving the final order of the Superior Court of Quebec and satisfaction of customary closing conditions, it is currently expected that the arrangement will be completed by mid-December, 2023.

The terms of the arrangement and the arrangement agreement between the corporation, Haemonetics and 9500-7704 Quebec Inc. dated Oct. 10, 2023, are further described in the management information circular and related materials for the meeting, all of which are available under the corporation's profile on SEDAR+.

About Opsens Inc.

Opsens focuses mainly on cardiology. The corporation offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fibre optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of more than 250,000 patients in more than 30 countries. It is approved for sale in the United States, the European Union, the United Kingdom, Japan and Canada.

Opsens has received FDA (U.S. Food and Drug Administration) clearance and Health Canada approval to commercialize the SavvyWire for transcatheter aortic valve replacement (TAVR) procedures. This unique guidewire is a three-in-one solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.

Opsens's SavvyWire is on trend with a minimalist approach to TAVR and advances the procedure, allowing patients to leave the hospital earlier, sometimes the same day. The TAVR procedure is growing rapidly globally, driven by the aging population and recent studies that demonstrate its benefits for a broader array of patients. The global TAVR market is expected to reach over 400,000 in 2025 and over 600,000 in 2030.

Opsens is also involved in industrial activities in developing, manufacturing and installing innovative fibre optic sensing solutions for critical applications.